(A) By using a specific anti-Anx-A1 antibody targeting the full-length of the protein, we were able to observe increase amounts of the protein in VKC patients compare to healthy controls. Interestingly, Anx-A1 level expression is decreased in VKC-treated patients with Lodoxomide. (B) By using a specific anti-Anx-A1 antibody targeting the N-terminal of the protein, we could measure the first amino acids that retain the entire intact N-terminal region. Interestingly, we could observe a small amount increase of the N-terminal region of Anx-A1 in VKC patients compare to the total measured (see (A)). However, VKC patients treated with Lodoxomide could show a same amount in the increase of N-terminal Anx-A1 compare to total (A).*p<0.05 ANOVA/Bonferroni test. (n=17 control group, n=23 VKC group and n=11 Lodoxomide treated group).
